Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CNS Pharmaceuticals, Inc. - Common Stock (NQ:CNSP)

5.090 -0.940 (-15.59%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CNS Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
20 21 Next >
Nottingham University Researchers Find Way to Make Brain Cancer Cells Self-Destruct
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Optimistic Berubicin May Provide Much-Needed Benefit for GBM Patients
Via Investor Brand Network
Microdevices to Enable Simultaneous Multiple Studies on Potential Brain Cancer Treatments
Via Investor Brand Network
Study Shares Insights on Why Brain Tumors Are Unresponsive to Immunotherapy
Via Investor Brand Network
CNS Pharmaceuticals (NASDAQ: CNSP) to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Via ACCESSWIRE
CNS Pharmaceuticals Reports Second Quarter 2023 Financial Results and Reiterates Upcoming Milestones
Via ACCESSWIRE
CNS Pharmaceuticals to Present at Benzinga's Virtual Biotech Conference
Via ACCESSWIRE
Researchers Trace Glioma Brain Tumor Origins to Epigenome
Via Investor Brand Network
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Looking Forward to Upcoming Interim Results for Potentially Pivotal GBM Study
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces 200-Patient Enrollment Milestone in Potentially Pivotal Berubicin Study
Via Investor Brand Network
CNS Pharmaceuticals (NASDAQ: CNSP) Reaches Milestone with Enrollment of 200 Patients in Ongoing Potentially Pivotal Study of Berubicin with the Treatment of Glioblastoma Multiforme (GBM)
Via ACCESSWIRE
Policies Encouraging High-Volume Facilities Disadvantage Oncology Patients in Rural Areas
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Participation at Upcoming H.C. Wainwright Global Investment Conference
Via Investor Brand Network
AI Helps Forecast Brain Tumor Outcomes
Via Investor Brand Network
Topics Artificial Intelligence
Canadian Researchers Design Powerful Imaging Tech to Boost Cancer Fight
Via Investor Brand Network
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Why Super League Gaming Are Trading Lower By Around 46%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) shares jumped 120% to $0.33. 
Via Benzinga
Researchers Develop Novel Way to Detect Pediatric Brain-Cancer Mutations
Via Investor Brand Network
How Healthcare eCommerce Impacts Traditional Providers of Healthcare
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Q2 2023 Results, Presents Updated Findings from Potentially Pivotal Study of Berubicin
Via Investor Brand Network
CNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Results from On-Going Potentially Pivotal Study of Berubicin in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy
Via ACCESSWIRE
Israeli Company Seeks to Develop Micro-Robots to Boost Precision Medicine
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin Distinguished with Unique Capabilities
Via Investor Brand Network
CNS Pharma's Lead Drug Candidate Crosses The Blood Brain Barrier - What Does That Mean? Watch the full show here!
Watch the full show here! John Climaco, Chairman & CEO of CNS Pharmaceuticals (NASDAQ: CNSP) presented at Benzinga’s webinar: Pharma Companies Vs. A Tough Macro Backdrop. 
Via Benzinga
Researchers Unlock Previously Unknown Weakness of Brain Cancer
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports on Berubicin Pivotal Study, Announces Participation in Biotech Conference
Via Investor Brand Network
CNS Pharmaceuticals Provides Clinical Trial Update for Ongoing Potentially Pivotal Study with Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
Via ACCESSWIRE
BioMedNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Abstract Selected for Poster Presentation at 2023 SNO/ASCO CNS Cancer Conference
Via Investor Brand Network
CNS Pharmaceuticals (NASDAQ:CNSP) Announces Acceptance of Abstract for Poster Presentation at the 2023 SNO/ASCO CNS Cancer Conference
Via ACCESSWIRE
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
20 21 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.